Introduction

 

Postbiotics are biologically active compounds generated during microbial fermentation or released from non-viable microorganisms that exert measurable health effects on the host. Unlike probiotics, which rely on live microorganisms, postbiotics include microbial metabolites, structural cell components, enzymes, peptides, polysaccharides, organic acids, and other bioactive molecules that can influence host physiology without requiring microbial viability (Żółkiewicz et al., 2020).

​

Interest in postbiotics and skin health in dogs has increased substantially as research has expanded beyond the gastrointestinal microbiome to encompass the interconnected gut–skin axis. Microbiome-derived compounds influence epithelial barrier integrity, cytokine production, innate immunity, oxidative stress, lipid metabolism, and microbial ecology, all of which contribute to canine dermatologic homeostasis.

​

Rather than acting through direct microbial colonization, postbiotics interact with host signaling pathways that regulate inflammation, immune tolerance, antimicrobial peptide production, and epidermal repair. These mechanisms are particularly relevant in diseases characterized by chronic immune dysregulation and microbial imbalance, including canine atopic dermatitis, food-responsive dermatosis, food allergies, and Malassezia dermatitis.

​

Within VetFarmacy, this article serves as the central mechanistic reference for postbiotics. Disease-specific nutritional management is discussed separately within the Canine Health Hub, the Canine Nutrition Hub, the Ingredient Hub, and the Nutritional Management of Canine Skin Health: Evidence Overview. Clinical applications connect these mechanisms with published evidence for Diet and Canine Atopic Dermatitis: Evidence-Based Nutritional Strategies, Food-Responsive Dermatosis, Food Allergies, and Malassezia Dermatitis.

​

Current research suggests that postbiotics influence multiple biological processes, including:

​

• modulation of inflammatory cytokines

• regulation of NF-κB and MAPK signaling pathways

• production of short-chain fatty acids

• maintenance of epithelial tight junctions

• regulation of lipid metabolism

• enhancement of antimicrobial peptide activity

• modulation of cutaneous and gastrointestinal microbiomes

• reduction of oxidative stress biomarkers

• promotion of immune tolerance through regulatory T-cell responses

 

These interconnected mechanisms position postbiotics as promising nutritional components within multimodal strategies targeting canine skin disease.

​

Biochemistry and Active Components

 

Molecular Characteristics

 

Postbiotics encompass a heterogeneous group of microbiome-derived compounds, not a single nutrient class. The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines postbiotics as preparations of inanimate microorganisms and/or their components that confer measurable health benefits to the host, provided biological activity has been demonstrated (Żółkiewicz et al., 2020).

​

Major categories include:

​

• Short-chain fatty acids (SCFAs)

  • Butyrate

  • Propionate

  • Acetate

• Exopolysaccharides

• Peptidoglycans

• Lipoteichoic acids

• Cell wall fragments

• Bacterial lysates

• Antimicrobial peptides

• Bacteriocins

• Bioactive enzymes

• Microbial-derived vitamins

• Indole metabolites

• Extracellular vesicles

 

Each compound possesses distinct biochemical properties and activates different cellular signaling pathways, explaining why postbiotics produce broad immunologic and metabolic effects despite lacking living microorganisms.

​

Short-Chain Fatty Acids

 

Among all postbiotic molecules, short-chain fatty acids in dogs remain the most extensively studied.

SCFAs are generated during bacterial fermentation of dietary fibers within the colon and function as important signaling molecules rather than simple metabolic by-products. While colonocytes consume over 70% to 80% of locally produced butyrate as their primary energy substrate, it also supports epithelial integrity, activates GPR109A, and modulates immune signaling; systemic SCFA concentrations in peripheral circulation are predominantly acetate and propionate (Pilla & Suchodolski, 2020).

​

Mechanistically, SCFAs:

​

• activate G-protein-coupled receptors (GPR41 and GPR43)

• inhibit histone deacetylases

• regulate NF-κB activation

• promote regulatory T-cell differentiation

• strengthen epithelial tight junction proteins

• influence lipid metabolism

• reduce production of pro-inflammatory cytokines

 

These molecular effects extend beyond the gastrointestinal tract, mediated through systemic distribution of circulating acetate and propionate and secondarily activated regulatory T lymphocytes originating from gut-associated lymphoid tissue, providing a key biological mechanism for the gut–skin axis in dogs. 

​

Microbial Structural Components

 

Non-viable bacterial cell components remain biologically active despite loss of microbial viability.

Important constituents include:

​

• peptidoglycans

• lipoteichoic acids

• surface-layer proteins

• exopolysaccharides

• membrane-associated proteins

 

These molecules interact directly with host pattern-recognition receptors, including Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) receptors.

​

Activation of these receptors initiates intracellular signaling pathways that regulate cytokine production, antimicrobial peptide synthesis, epithelial differentiation, and innate immune responses.

​

Rather than stimulating indiscriminate inflammation, controlled activation supports immune education and mucosal homeostasis, an effect increasingly recognized in canine microbiome research (Wilson & Swanson, 2024).

​

Absorption, Distribution, and Metabolism

 

Unlike conventional nutrients that require systemic absorption to exert biological effects, many postbiotics act locally at epithelial surfaces before producing downstream systemic consequences.

​

Within the gastrointestinal tract, microbial metabolites interact with epithelial cells, dendritic cells, macrophages, and resident lymphocytes embedded within gut-associated lymphoid tissue. These interactions alter intracellular signaling pathways regulating cytokine production, oxidative stress responses, epithelial permeability, and metabolic activity.

​

Certain metabolites—including butyrate and indole derivatives—enter the portal circulation and subsequently influence distant organs, including the liver, immune system, and skin, through endocrine-like signaling networks.

​

Current evidence indicates that postbiotic-mediated physiological effects depend upon:

​

• microbial metabolite composition

• dietary substrate availability

• intestinal microbial diversity

• epithelial permeability

• host immune status

• existing microbiome composition

 

Consequently, biological activity varies substantially among individual dogs despite administration of similar postbiotic preparations.

​

Emerging canine microbiome studies further suggest that dietary modulation of microbial metabolite production alters both gastrointestinal and cutaneous microbial communities, reinforcing the concept that microbiome-derived compounds influence skin biology through integrated gut–skin communication pathways (Dehcheshmeh et al., 2025; Grant et al., 2025).

 

These mechanistic relationships provide the foundation for understanding how postbiotics influence inflammatory signaling, biomarkers of immune activation, lipid metabolism, and skin barrier integrity discussed in the following section.

​

Mechanisms of Action

 

Postbiotics exert biological activity through complex interactions between microbial metabolites and host signaling pathways rather than through colonization of the gastrointestinal tract. Their physiological effects extend across the intestinal epithelium, immune system, skin, and metabolic tissues, providing mechanistic support for the gut–skin axis in dogs.

​

Although individual postbiotic compounds differ in molecular structure, many converge on common biological pathways involving cytokines, nuclear transcription factors, epithelial barrier regulation, oxidative stress responses, and lipid metabolism.

​

Several of these mechanisms overlap with concepts discussed in the VetFarmacy Evidence Library topics on Gut Microbiome and Digestive Health and Inflammation and Nutritional Modulation, highlighting how microbiome-derived compounds influence both local and systemic physiology.

​

Anti-inflammatory Pathways

 

One of the best-characterized biological activities of postbiotics is modulation of inflammatory signaling. Rather than functioning as broad immunosuppressive agents, postbiotics promote immune homeostasis by regulating cytokine production and intracellular signaling networks that coordinate innate and adaptive immunity.

​

Short-chain fatty acids, particularly butyrate, inhibit activation of nuclear factor-kappa B (NF-κB), a transcription factor that induces numerous pro-inflammatory mediators. Suppression of NF-κB signaling reduces transcription of cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and other mediators implicated in chronic inflammatory skin disease (Stec et al., 2023; Coppola et al., 2022).

​

Postbiotics also influence mitogen-activated protein kinase (MAPK) signaling pathways, further regulating inflammatory gene expression and cellular stress responses. At the same time, microbial metabolites stimulate the production of anti-inflammatory cytokines such as IL-10 while promoting differentiation of regulatory T lymphocytes (Tregs), which contribute to immune tolerance and prevent excessive inflammatory responses.

​

Additional mechanisms include:

​

• reduced activation of NF-κB signaling pathways

• modulation of MAPK-mediated inflammatory cascades

• decreased production of TNF-α, IL-1β, IL-6, and IL-17

• enhanced IL-10 secretion

• increased regulatory T-cell activity

• reduced oxidative stress–associated inflammatory biomarkers

 

These coordinated effects are particularly relevant in canine dermatologic disorders characterized by persistent cytokine dysregulation and chronic cutaneous inflammation, including atopic dermatitis and food-associated skin disease (Santoro et al., 2023; Kim et al., 2025).

​

Metabolic Effects

 

Beyond immune modulation, postbiotics influence numerous metabolic processes that indirectly affect skin health.

Short-chain fatty acids act as signaling molecules that regulate lipid metabolism, glucose utilization, mitochondrial activity, and cellular energy production. Butyrate serves as the preferred energy substrate for colonocytes, improving epithelial function while reducing metabolic stress associated with intestinal inflammation (Pilla & Suchodolski, 2020).

​

Activation of G-protein-coupled receptors (GPR41 and GPR43) initiates downstream signaling pathways that influence:

​

• fatty acid oxidation

• lipid synthesis

• insulin sensitivity

• mitochondrial respiration

• epithelial energy metabolism

• immune cell metabolism

 

These metabolic adaptations help maintain intestinal barrier integrity and may indirectly reduce systemic inflammatory burden by decreasing translocation of microbial products.

​

Emerging evidence also suggests interactions with peroxisome proliferator-activated receptor-gamma (PPAR-γ), a specific nuclear receptor isoform that regulates epidermal lipid metabolism, keratinocyte differentiation, and cutaneous inflammatory gene expression. Although direct canine evidence remains limited, these pathways offer biologically plausible explanations for observed improvements in skin barrier function following microbiome-directed nutritional interventions (Prajapati et al., 2025; Rušanac et al., 2025).

​

Mechanistically, postbiotics may therefore influence:

​

• epidermal lipid synthesis

• ceramide metabolism

• sebaceous gland homeostasis

• oxidative phosphorylation

• intestinal nutrient utilization

• systemic inflammatory biomarkers

 

These mechanisms complement broader nutritional discussions presented in the VetFarmacy Evidence Library article on Lipid Metabolism and Inflammation in Dogs.

​

Cellular Signaling

 

The biological activity of postbiotics depends largely on their interaction with cellular receptors rather than direct nutritional supplementation.

​

Microbial metabolites bind multiple receptor systems, including:

​

• Toll-like receptors (TLR2 and TLR4)

• nucleotide-binding oligomerization domain (NOD) receptors

• aryl hydrocarbon receptor (AhR)

• GPR41

• GPR43

• GPR109A

 

Activation of these receptors initiates intracellular signaling cascades regulating epithelial proliferation, antimicrobial peptide synthesis, cytokine secretion, apoptosis, oxidative stress responses, and cellular differentiation.

​

Among the most important downstream pathways are:

​

• NF-κB signaling

• MAPK signaling

• JAK–STAT signaling

• Nrf2 antioxidant signaling

• PI3K/Akt signaling

 

Together, these signaling pathways coordinate communication between epithelial cells, dendritic cells, macrophages, neutrophils, and lymphocytes, integrating microbial-derived molecular signals into broader immune responses.

​

Recent in vitro cell culture research using canine keratinocytes indicates that culture supernatants derived from canine-associated beneficial bacteria stimulate pathways involved in cellular viability, wound repair, and epithelial resilience; however, while these cell culture findings demonstrate direct metabolite-level biological activity, they do not reflect in vivo clinical outcomes in dogs with naturally occurring skin disease (Kim et al., 2026).

​

Another emerging area involves microbial indole metabolites, which activate the aryl hydrocarbon receptor (AhR). AhR signaling regulates epidermal differentiation, skin barrier maturation, oxidative stress responses, and antimicrobial defense. A randomized placebo-controlled canine trial demonstrated that an indole-rich postbiotic reduced pruritus in dogs, providing one of the strongest direct clinical demonstrations of postbiotic-mediated dermatologic benefit in veterinary medicine (Sordillo et al., 2025).

​

Organ and System-Level Effects

​

Gastrointestinal System

 

The gastrointestinal tract remains the principal site where postbiotics exert biological activity.

​

Within the intestinal mucosa, microbial metabolites strengthen epithelial tight junction proteins, including occludin, claudins, and zonula occludens proteins, thereby reducing intestinal permeability. Improved epithelial integrity limits translocation of bacterial endotoxins and other inflammatory stimuli into systemic circulation.

​

Additional gastrointestinal effects include:

​

• improved epithelial barrier function

• maintenance of microbial diversity

• increased mucin production

• enhanced secretory IgA activity

• regulation of intestinal immune tolerance

• modulation of gastrointestinal biomarkers associated with inflammation

 

These mechanisms explain why gastrointestinal health frequently precedes improvements in extraintestinal disorders involving immune dysregulation.

​

Immune System

 

Approximately 70% of immune tissue resides within the gastrointestinal tract, making intestinal microbiome activity central to systemic immune regulation.

​

Postbiotics influence both innate and adaptive immunity by modulating dendritic cells, macrophages, neutrophils, regulatory T cells, and B lymphocytes. Rather than stimulating generalized immune activation, they appear to promote balanced immune responsiveness while limiting excessive inflammatory signaling.

​

Experimental studies consistently show reductions in inflammatory cytokines alongside increased immune tolerance, supporting their potential role in chronic inflammatory diseases involving dysregulated cytokine networks (Ashkanani et al., 2025; Guéniche et al., 2022).

​

Integumentary System

 

The skin represents one of the most clinically relevant downstream targets of microbiome-derived compounds.

​

Current evidence indicates that gut microbial metabolites influence:

​

• epidermal barrier integrity

• keratinocyte differentiation

• antimicrobial peptide expression

• skin microbial diversity

• oxidative stress

• inflammatory cytokines

• lipid metabolism

• wound healing

 

Canine studies show that modulating the gastrointestinal microbiome alters the composition of the cutaneous microbiome, supporting bidirectional communication between intestinal and skin microbial ecosystems (Grant et al., 2025; Dehcheshmeh et al., 2025).

​

Healthy canine skin contains a diverse microbial community that supports host defense, immune education, and barrier function. Dysbiosis disrupts these protective interactions and is consistently associated with inflammatory skin disorders, including canine atopic dermatitis (Whittle et al., 2024; Bradley et al., 2016; Chermprapai et al., 2019).

​

Collectively, these organ-level interactions illustrate why postbiotics should not be viewed solely as gastrointestinal metabolites. Instead, they function as microbiome-derived signaling molecules that influence interconnected physiological systems through coordinated effects on inflammation, epithelial biology, immune regulation, lipid metabolism, and cellular communication.

​

Clinical Applications Across Conditions

 

Current evidence indicates that postbiotics influence multiple biological processes relevant to canine dermatologic disease by modulating the gut–skin axis, immune regulation, epithelial barrier function, microbial ecology, and inflammatory signaling pathways. However, evidence strength varies considerably across conditions. The following sections summarize only applications supported by published veterinary or high-quality translational evidence.

​

Canine Atopic Dermatitis

 

Mechanism: Canine atopic dermatitis (CAD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction, microbial dysbiosis, altered lipid metabolism, and dysregulated cytokine signaling involving T helper 2 (Th2)-dominant immune responses. Increased expression of IL-4, IL-13, IL-31, thymic stromal lymphopoietin (TSLP), and other inflammatory mediators contributes to persistent pruritus, impaired skin barrier integrity, and recurrent secondary infections (Santoro et al., 2023).

​

Postbiotics may influence these disease pathways through several complementary mechanisms:

​

• suppression of NF-κB-mediated inflammatory signaling

• modulation of IL-4, IL-13, IL-31, and TNF-α production

• enhancement of regulatory T-cell activity

• improvement of epithelial tight junction integrity

• support of epidermal lipid metabolism

• modulation of cutaneous microbial diversity

• reduction of oxidative stress biomarkers

 

Microbiome-derived short-chain fatty acids and indole metabolites also promote immune tolerance while limiting excessive activation of innate immune pathways. These mechanisms support restoration of microbial homeostasis across both the gastrointestinal tract and skin.

​

Evidence: Growing canine evidence supports microbiome-directed nutritional interventions in atopic dermatitis.

Longitudinal sequencing studies demonstrate that dogs with atopic dermatitis exhibit marked alterations in skin microbial composition compared with healthy controls, with microbial diversity improving during successful treatment (Bradley et al., 2016).

​

Additional microbiome investigations confirmed dysbiosis involving both bacterial and fungal communities in canine atopic dermatitis while demonstrating changes following antimicrobial therapy (Chermprapai et al., 2019).

​

Comprehensive microbiome analyses further support coordinated alterations involving both gut and skin microbial ecosystems in affected dogs, strengthening the biological basis of the gut–skin axis (Thomsen et al., 2022).

​

More recently, randomized canine studies evaluating microbiome-modulating interventions have demonstrated improvements in pruritus, microbiome composition, and inflammatory status, although most have investigated combined probiotic and postbiotic approaches rather than isolated postbiotics (Huang et al., 2025; Song et al., 2025).

​

One of the strongest direct canine studies evaluated an indole-rich postbiotic in a randomized, double-blind, placebo-controlled trial, showing reduced pruritus in affected dogs and supporting postbiotic-mediated modulation of inflammatory signaling (Sordillo et al., 2025).

​

Clinical Interpretation

 

Strength of evidence: Moderate to Strong

​

Current veterinary evidence supports postbiotics as promising adjunctive nutritional components targeting microbiome-derived inflammatory pathways in canine atopic dermatitis. Although long-term studies evaluating isolated postbiotic formulations remain limited, mechanistic consistency and emerging canine clinical trials provide biologically plausible support for their inclusion within multimodal nutritional management.

​

The VetFarmacy article on Diet and Canine Atopic Dermatitis: Evidence-Based Nutritional Strategies discusses further disease-specific nutritional strategies.

​

Food Allergies in Dogs

 

Mechanism: Food allergies involve inappropriate immune recognition of dietary proteins, leading to chronic activation of adaptive immune responses affecting both the gastrointestinal tract and skin.

​

Postbiotics do not eliminate dietary allergens but may influence disease biology by:

​

• enhancing intestinal epithelial integrity

• reducing intestinal permeability

• promoting immune tolerance

• decreasing inflammatory cytokine production

• regulating dendritic cell activation

• supporting beneficial microbial metabolite production

 

Because intestinal barrier dysfunction contributes to abnormal antigen exposure, restoring epithelial integrity is one proposed mechanism by which microbiome-derived compounds may reduce inflammatory amplification.

 

Evidence: Current canine evidence remains indirect.

​

Most published studies evaluate microbiome modulation rather than isolated postbiotic administration. Nevertheless, mechanistic investigations consistently demonstrate interactions among intestinal permeability, microbial metabolites, immune regulation, and allergic inflammation (Pilla & Suchodolski, 2020; Wilson & Swanson, 2024).

​

Recent reviews further suggest that microbial metabolites influence immune tolerance by regulating regulatory T cells, epithelial signaling pathways, and cytokine production, supporting the biological plausibility of adjunctive nutritional strategies targeting food-associated inflammatory disease (Stec et al., 2023; Micu et al., 2025).

​

Clinical Interpretation

 

Strength of evidence: Limited (Mechanistic & Indirect) 

Evidence currently supports postbiotics as adjunctive modulators of immune homeostasis rather than primary nutritional therapy. Elimination diets remain the diagnostic and therapeutic cornerstone, while postbiotics offer a complementary strategy to restore gut microbial ecology and epithelial barrier function.

​

Related dietary management is discussed in Food Allergies in Dogs: Nutritional Management and Elimination Diet Evidence.

​

Food-Responsive Dermatosis

 

Mechanism: Food-responsive dermatosis encompasses dermatologic disease that improves after eliminating dietary triggers. Although clinical manifestations overlap with food allergy, the disease involves interactions among gastrointestinal barrier integrity, microbial ecology, inflammatory cytokines, and immune regulation.

​

Potential postbiotic actions include:

​

• stabilization of intestinal barrier function

• modulation of gut-associated lymphoid tissue

• reduction of systemic inflammatory biomarkers

• support of epithelial lipid metabolism

• enhancement of microbial diversity

• regulation of cytokine signaling pathways

 

Collectively, these effects may reduce the spread of inflammatory responses beyond the gastrointestinal tract.

 

Evidence: Direct veterinary trials specifically evaluating postbiotics in food-responsive dermatosis remain unavailable.

Support currently comes from mechanistic studies involving microbial metabolites, along with broader canine microbiome research demonstrating relationships among gastrointestinal dysbiosis, immune regulation, and dermatologic disease.

​

Systematic reviews of canine postbiotic interventions also identify dermatologic health as an emerging area that requires additional randomized controlled trials before definitive clinical conclusions can be established (Bonel-Ayuso et al., 2025).

​

Clinical Interpretation

 

Strength of evidence: Limited to Moderate

​

Current evidence supports biological plausibility but remains insufficient to recommend postbiotics as standalone nutritional therapy. Their greatest value appears to lie in comprehensive nutritional programs that address both elimination diets and microbiome restoration.

​

Further discussion is provided in Food-Responsive Dermatosis in Dogs: Nutritional Evidence and Diagnostic Diets.

​

Malassezia Dermatitis

 

Mechanism: Malassezia dermatitis develops through complex interactions involving altered skin barrier function, microbial imbalance, excessive inflammatory signaling, and local immune dysregulation.

​

Rather than directly inhibiting fungal proliferation, postbiotics may improve the cutaneous environment through:

​

• enhancement of epidermal barrier integrity

• modulation of antimicrobial peptide production

• reduction of inflammatory cytokines

• restoration of microbial ecological balance

• regulation of oxidative stress

• support of keratinocyte differentiation

 

Improved epithelial resilience may indirectly reduce conditions favoring Malassezia overgrowth.

​

Evidence: Current canine evidence remains largely mechanistic.

​

Studies consistently show microbial dysbiosis in dogs with allergic skin disease, including altered bacterial and fungal populations that influence disease progression (Chermprapai et al., 2019).

​

Reviews of microbiome-targeted dermatologic therapies increasingly recognize postbiotics as promising adjunctive interventions that can influence microbial ecology, inflammatory pathways, and epithelial repair, although no direct canine Malassezia trials have been published (Guéniche et al., 2022; Lagoa et al., 2025).

​

Clinical Interpretation

 

Strength of evidence: Limited

 

Current evidence supports potential adjunctive use to improve skin barrier biology and microbial homeostasis rather than direct antifungal activity. Disease-specific recommendations continue to depend primarily on established dermatologic management strategies while canine postbiotic research evolves.

​

Related nutritional discussion is available in Malassezia Dermatitis in Dogs: Nutritional Support and Clinical Evidence.

​

Cutaneous Wound Healing and Skin Barrier Repair

 

Mechanism: Beyond inflammatory skin disease, postbiotics influence biological pathways associated with tissue repair.

Microbiome-derived compounds stimulate:

​

• keratinocyte proliferation

• fibroblast activity

• collagen remodeling

• angiogenesis

• antimicrobial peptide synthesis

• epithelial differentiation

• oxidative stress regulation

 

Short-chain fatty acids and microbial peptides additionally activate signaling pathways involved in cellular migration and wound closure while reducing excessive inflammatory responses.

​

Evidence: Most evidence derives from mechanistic studies and experimental wound models.

​

Recent reviews consistently demonstrate that postbiotics regulate multiple molecular pathways involved in wound repair, including cytokine modulation, growth factor expression, extracellular matrix remodeling, and epithelial regeneration (Dinić et al., 2025; Hashemi et al., 2025; Machado et al., 2025).

​

Canine-specific evidence remains limited to preliminary in vitro cell monolayer models demonstrating beneficial effects of canine-derived postbiotic metabolites on keratinocyte viability and cell migration, requiring in vivo clinical trial confirmation before translating to actual canine wound healing (Kim et al., 2026).

​

Clinical Interpretation

 

Strength of evidence: Limited (Translational)

​

Current findings provide mechanistic support for future veterinary investigation but remain insufficient for routine clinical recommendations in dogs. Additional randomized canine trials evaluating naturally occurring dermatologic wounds and barrier disorders are needed.

​

The collective evidence indicates that postbiotics exert their greatest clinical potential by modulating shared biological mechanisms—including inflammation, cytokine signaling, epithelial integrity, lipid metabolism, oxidative stress, and microbial ecology—rather than through disease-specific effects. This systems-based activity explains why ongoing research increasingly views postbiotics as supportive components of multimodal nutritional strategies spanning multiple dermatologic conditions rather than isolated therapeutic agents.

​

Dosage and Clinical Use

 

Unlike essential nutrients with established dietary requirements, postbiotics currently lack standardized therapeutic dosage recommendations in canine nutrition. Biological activity depends on the specific postbiotic preparation, its constituent microbial metabolites, manufacturing process, and intended clinical application rather than on a single active compound.

Consequently, published canine studies have evaluated heterogeneous postbiotic preparations, making direct comparisons among investigations difficult (Bonel-Ayuso et al., 2025).

​

Current veterinary research has investigated postbiotics in several forms:

​

• Heat-inactivated bacterial preparations

• Fermentation metabolites

• Culture supernatants

• Cell-free microbial extracts

• Purified short-chain fatty acids

• Microbial lysates

• Functional ingredients incorporated into complete diets

• Oral nutritional supplements

 

Because each preparation differs in metabolite composition and biological activity, evidence does not currently support extrapolating dosage between products.

​

Therapeutic Versus Maintenance Use

 

Published studies primarily evaluate postbiotics as adjunctive nutritional interventions rather than maintenance nutrients.

Investigated clinical contexts include:

​

• chronic inflammatory skin disease

• pruritic dermatitis

• microbiome dysbiosis

• gastrointestinal barrier dysfunction

• immune modulation

• epithelial repair

 

Current evidence supports integrating postbiotics within broader nutritional strategies targeting inflammation, microbial ecology, and barrier function rather than relying on isolated supplementation.

​

Bioavailability

 

Bioavailability differs substantially among postbiotic compounds.

​

Unlike probiotics, postbiotics do not need to survive gastric acidity or colonize the intestine to exert biological effects.

 

Instead, activity depends on:

​

• stability during manufacturing

• preservation of bioactive metabolites

• interaction with epithelial receptors

• receptor affinity

• intestinal absorption of selected metabolites

• local gastrointestinal activity

• downstream signaling pathways

 

Short-chain fatty acids such as butyrate exert prominent local metabolic effects within the colon, whereas peripheral organ systems like the skin are reached primarily through systemic circulation of absorbed acetate and propionate, as well as downstream immunologic cascades induced within the gut mucosa. 

​

Other microbial-derived compounds interact directly with intestinal epithelial cells, dendritic cells, and macrophages without requiring systemic distribution.

​

These pharmacodynamic characteristics distinguish postbiotics from both probiotics and conventional nutritional ingredients.

​

Safety and Limitations

 

Current veterinary literature indicates that postbiotics possess a favorable safety profile because they do not contain viable microorganisms capable of replication or translocation.

​

Elimination of microbial viability reduces theoretical risks associated with administering live organisms while preserving many biologically active microbial metabolites.

​

Reported adverse effects within canine studies have generally been minimal and transient, although long-term safety data remain limited (Bonel-Ayuso et al., 2025).

​

Potential considerations include:

​

• batch-to-batch variability stemming from differences in fermentation parameters (e.g., substrate composition, pH, and thermal inactivation method) 

• inconsistent metabolite profiles 

• lack of standardized definitions across products 

• limited disease-specific dosing studies

• insufficient long-term randomized controlled trials

 

Unlike pharmaceuticals, postbiotics represent complex mixtures of biologically active compounds. As a result, two preparations described as "postbiotics" may differ considerably in molecular composition and biological activity.

​

Contraindications

 

Canine clinical studies have identified no consistent contraindications.

​

However, caution should be exercised when interpreting evidence because:

​

• individual formulations differ substantially

• most studies evaluate combination interventions

• dermatologic outcome measures vary among trials

• optimal duration of administration remains unknown

 

Postbiotics should therefore be interpreted as supportive nutritional components within multimodal management rather than replacements for established dermatologic therapies.

​

Evidence Gaps

 

Despite rapid growth in microbiome research, several important knowledge gaps remain.

​

Current limitations include:

​

• few randomized canine trials evaluating isolated postbiotics

• heterogeneous definitions of postbiotic preparations

• limited standardized biomarkers across studies

• insufficient long-term dermatologic outcome data

• limited comparisons among different postbiotic compounds

• uncertainty regarding optimal therapeutic dosing

 

Additional investigations are particularly needed to determine whether specific microbial metabolites consistently improve clinical outcomes across individual dermatologic diseases.

Interpret the current literature alongside the VetFarmacy Evidence Library articles on Limitations of Veterinary Clinical Trials and Translating Human Nutrition Studies to Pets, both of which discuss challenges in interpreting emerging nutritional evidence.

​

Evidence Summary

 

Current evidence supports postbiotics as biologically active, microbiome-derived compounds that can influence inflammatory signaling, epithelial barrier integrity, immune regulation, oxidative stress, lipid metabolism, and microbial ecology.

​

The strongest mechanistic evidence involves:

​

• modulation of cytokines

• inhibition of NF-κB signaling

• regulation of MAPK pathways

• enhancement of epithelial barrier function

• promotion of microbial diversity

• production of short-chain fatty acids

• regulation of immune tolerance

 

Veterinary clinical evidence continues to expand, particularly regarding microbiome-directed nutritional interventions for canine dermatologic disease.

​

The highest-quality canine evidence currently supports:

​

• modulation of the gut–skin axis

• improvement of microbial diversity

• reduction of pruritus

• restoration of skin microbiome composition

• adjunctive nutritional support for inflammatory skin disease

 

Conversely, several proposed applications—including wound healing, direct antifungal activity, and disease-specific postbiotic formulations—remain supported primarily by mechanistic and translational evidence rather than robust canine clinical trials.

​

Overall, postbiotics should presently be viewed as supportive nutritional tools targeting shared biological pathways rather than disease-specific therapeutic agents.

​

Strength of Evidence by Condition

​​

​

​

​

​

​

​

​

​

​​​​

​​

​

​

​

​​​​​​​​​​

Overall evidence quality can be summarized as follows:

​

Strong evidence

​

• Gut–skin axis interactions

• Microbiome modulation

• Cytokine regulation

• Inflammatory signaling pathways

• Skin microbial ecology

 

Moderate evidence

​

• Skin barrier support

• Lipid metabolism

• Immune tolerance

• Reduction of pruritus

• Biomarker modulation

 

Limited / Extrapolated evidence

​

• Disease-specific postbiotic formulations

• Long-term maintenance protocols

• Comparative effectiveness among different postbiotic preparations

• Standardized therapeutic dosing

• Direct canine wound-healing applications

 

The current literature consistently supports the biological plausibility of postbiotics in canine clinical nutrition while emphasizing the need for additional randomized veterinary trials evaluating standardized formulations, clinically meaningful biomarkers, and long-term dermatologic outcomes.

​

Practical Clinical Integration

 

Current evidence supports incorporating postbiotics into canine clinical nutrition as part of a systems-based approach that targets shared biological mechanisms rather than individual diseases. Their primary value lies in modulating host–microbiome interactions that influence inflammation, epithelial integrity, immune homeostasis, and microbial ecology across multiple organ systems.

​

Clinical scenarios in which postbiotics may have the greatest relevance include:

​

• Chronic inflammatory skin disease associated with microbial dysbiosis

• Nutritional support during multimodal management of canine atopic dermatitis

• Restoration of gut–skin axis function following gastrointestinal dysbiosis

• Support of epithelial barrier integrity in chronic dermatologic disorders

• Adjunctive nutritional strategies targeting inflammatory cytokines and oxidative stress

 

Because postbiotics act through microbiome-derived signaling pathways, they should be considered complementary to—not replacements for—established dietary interventions. For example, elimination diets remain the cornerstone of food allergy diagnosis, while therapeutic dermatologic diets continue to address nutrient modification, allergen avoidance, and skin barrier support.

​

Emerging evidence also suggests biological synergy with other functional nutrients discussed throughout VetFarmacy, including:

​

• Essential fatty acids, which influence eicosanoid production and lipid metabolism.

• Zinc, which supports epidermal turnover, immune function, and antioxidant enzyme activity.

• Ceramides, which contribute directly to stratum corneum barrier integrity.

 

Collectively, these nutrients target overlapping biological pathways involving cytokines, membrane biology, oxidative stress, and epithelial repair, reinforcing the importance of multimodal nutritional strategies rather than reliance on single ingredients.

As additional randomized canine trials become available, postbiotics may assume a larger role within evidence-based veterinary dermatology.

​

Related Conditions

 

Readers interested in disease-specific nutritional management should explore the following VetFarmacy clinical resources:

Published

​

• Diet and Canine Atopic Dermatitis: Evidence-Based Nutritional Strategies

• Food-Responsive Dermatosis in Dogs: Nutritional Evidence and Diagnostic Diets

• Food Allergies in Dogs: Nutritional Management and Elimination Diet Evidence

• Malassezia Dermatitis in Dogs: Nutritional Support and Clinical Evidence

 

Related ingredient pages include:

​

• Essential Fatty Acids and Skin Health in Dogs: Mechanisms Beyond Omega-3 

• Zinc in Canine Nutrition: Gut, Skin, and Immune Function

• Ceramides and Skin Barrier Lipids in Dogs: Nutritional Implications

 

For broader clinical context, readers may also consult:

​

• Canine Health Hub

• Canine Nutrition Hub

• Ingredient Hub

• Nutritional Management of Canine Skin Health: Evidence Overview

• Nutritional Management of the Canine Gastrointestinal System: Evidence Overview

​​

Evidence Notes

​

Overall Strength of Evidence

 

Strong evidence

​

• Gut–skin axis biology

• Microbiome dysbiosis in canine atopic dermatitis

• Cytokine modulation

• NF-κB signaling

• Skin microbiome alterations

• Gastrointestinal microbial metabolites

 

Moderate evidence

​

• Reduction of pruritus

• Immune tolerance

• Barrier function

• Lipid metabolism

• Oxidative stress regulation

• Biomarker improvement

 

Limited / Extrapolated evidence

​

• Disease-specific postbiotic formulations

• Long-term therapeutic dosing

• Direct treatment of Malassezia dermatitis

• Wound healing in naturally occurring canine disease

• Comparative efficacy among different postbiotic preparations

​​

Current Research Gaps

 

Several important questions remain unanswered:

​

• Which microbial metabolites provide the greatest clinical benefit?

• Which biomarkers best predict treatment response?

• Are certain dermatologic diseases more responsive than others?

• What constitutes the optimal therapeutic dosage?

• Which manufacturing methods preserve the most biologically active compounds?

• How long should postbiotics be administered for chronic inflammatory disease?

​​

Translational Considerations

 

Much of the mechanistic understanding of postbiotics originates from human dermatology, immunology, and microbiome research. While these findings provide important biological insight, direct extrapolation to canine patients should be undertaken cautiously because of species differences in:

​

• skin physiology

• microbial ecology

• immune regulation

• gastrointestinal metabolism

• dietary requirements

 

Accordingly, this article prioritizes canine clinical studies whenever available while clearly distinguishing mechanistic and translational evidence from established veterinary clinical outcomes.

​

Clinical Outcomes Evidence Summary

​​

​

​

​

​

​

​

​

​

​

​

​

​

​

​